MXPA02002772A - Virus oncolitico. - Google Patents

Virus oncolitico.

Info

Publication number
MXPA02002772A
MXPA02002772A MXPA02002772A MXPA02002772A MXPA02002772A MX PA02002772 A MXPA02002772 A MX PA02002772A MX PA02002772 A MXPA02002772 A MX PA02002772A MX PA02002772 A MXPA02002772 A MX PA02002772A MX PA02002772 A MXPA02002772 A MX PA02002772A
Authority
MX
Mexico
Prior art keywords
virus
tumor cell
pkr
stat1
oncolytic virus
Prior art date
Application number
MXPA02002772A
Other languages
English (en)
Inventor
Cameron Bell John
Original Assignee
Pro Virus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pro Virus Inc filed Critical Pro Virus Inc
Publication of MXPA02002772A publication Critical patent/MXPA02002772A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20261—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invencion se dirige a un metodo para reducir la viabilidad de una celula de tumor que implica administrar un virus que no es un patogeno humano comun a la celula de tumor. Preferiblemente, el virus exhibe susceptibilidad diferencial, porque las celulas normales no son afectadas por el virus. Esta susceptibilidad diferencial es mas pronunciada en la presencia de interferon. La celula de tumor se caracteriza por tener niveles bajos, o no tener, actividad PKR, o por ser PKR-/-, STATI-/- o tanto PKR-/- como STAT1-/-. El virus se selecciona del grupo que consiste en Rabdovirus y picornavirus, y preferiblemente es el virus de estomatitis vesicular (VSV) o un derivado del mismo.
MXPA02002772A 1999-09-17 2000-09-18 Virus oncolitico. MXPA02002772A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39787399A 1999-09-17 1999-09-17
PCT/US2000/025510 WO2001019380A2 (en) 1999-09-17 2000-09-18 Oncolytic virus

Publications (1)

Publication Number Publication Date
MXPA02002772A true MXPA02002772A (es) 2004-04-02

Family

ID=23573018

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02002772A MXPA02002772A (es) 1999-09-17 2000-09-18 Virus oncolitico.

Country Status (13)

Country Link
EP (2) EP1218019B1 (es)
JP (1) JP5060694B2 (es)
CN (1) CN1289098C (es)
AT (2) ATE418341T1 (es)
AU (1) AU782402B2 (es)
CA (1) CA2386920C (es)
DE (2) DE60041210D1 (es)
ES (2) ES2260057T3 (es)
HK (2) HK1044708B (es)
IL (2) IL148621A0 (es)
MX (1) MXPA02002772A (es)
NZ (4) NZ534306A (es)
WO (1) WO2001019380A2 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
IL153570A0 (en) 2000-06-26 2003-07-06 Wellstat Biologics Corp Purging of cells using viruses
CA2442648C (en) 2001-05-11 2012-10-16 Pro-Virus, Inc. Oncolytic virus therapy
AU2008201293B2 (en) * 2001-07-11 2011-08-18 University Of Miami Recombinant VSV for the treatment of tumor cells
EP1411880B1 (en) * 2001-07-11 2018-04-25 University of Miami Recombinant vsv for the treatment of tumor cells
JP2004099584A (ja) 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
EP2039773B1 (en) * 2003-03-27 2011-12-28 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and use thereof
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
US8012747B2 (en) 2004-06-01 2011-09-06 San Diego State University Foundation Expression system
WO2006017914A1 (en) 2004-08-20 2006-02-23 Viralytics Limited Methods and compositions for treatment of hematologic cancers
CN101065144B (zh) * 2004-08-20 2012-06-13 溶瘤病毒有限公司 治疗血液癌症的方法和组合物
US10260049B2 (en) 2005-08-01 2019-04-16 Virocure, Inc. Attenuated reovirus
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
EP2839837B1 (en) * 2006-09-15 2019-05-08 Children's Hospital of Eastern Ontario Research Institute Inc. Oncolytic farmington rhabdovirus
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
US20090175906A1 (en) * 2007-12-21 2009-07-09 Wyeth Genetically Modified Attenuated Vesicular Stomatitis Virus, Compositions and Methods of use Thereof
JP2012500229A (ja) 2008-08-21 2012-01-05 オタワ ホスピタル リサーチ インスティチュート 遺伝子操作された相乗的腫瘍溶解性ウイルス共生
DE102008050860A1 (de) * 2008-10-08 2010-04-15 Dorothee Von Laer LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren
CN102448487B (zh) 2009-03-16 2016-03-16 麦克马斯特大学 疫苗接种方法
US9045729B2 (en) * 2009-12-10 2015-06-02 Ottawa Hospital Research Institute Oncolytic rhabdovirus
US9951117B2 (en) 2010-09-02 2018-04-24 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
US9428736B2 (en) * 2010-09-02 2016-08-30 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
WO2012167382A1 (en) 2011-06-08 2012-12-13 Children's Hospital Of Eastern Ontario Research Institute Inc. Compositions and methods for glioblastoma treatment
ES2698076T3 (es) 2011-10-07 2019-01-30 Isd Immunotech Aps Identificación de los dominios inmunosupresores en las proteínas de fusión de los virus de ARN con envoltura
WO2014127478A1 (en) 2013-02-21 2014-08-28 Children's Hospital Of Eastern Ontario Research Institute Inc. Vaccine composition
US11484567B2 (en) 2013-04-10 2022-11-01 Aarhus Universitet Use of immune suppressive domains as medicaments
EP3008176B1 (en) 2013-06-14 2019-08-07 Turnstone Limited Partnership Compositions and methods for enhancing virus replication
PL2826856T3 (pl) * 2013-07-16 2016-06-30 Sia Latima Genetycznie stabilny onkolityczny wirus RNA, sposób jego wytwarzania i zastosowanie
JP6837428B2 (ja) 2014-07-21 2021-03-10 ノベルラスディクス リミテッド 患者特有の変異の発癌性指数を決定する方法およびシステム
CN105233285B (zh) * 2015-09-06 2018-10-12 广州威溶特医药科技有限公司 Epac直接或间接激动剂与溶瘤病毒的联合应用
US10610583B2 (en) 2017-08-31 2020-04-07 Regents Of The University Of Minnesota Methods and compositions for treating glioma and medulloblastoma brain tumors using the zika virus
US20200216502A1 (en) * 2017-09-22 2020-07-09 Centre National De La Recherche Scientifique (Cnrs) Mutated Glycoprotein of Vesicular Stomatitis Virus
CN110499297B (zh) * 2019-08-29 2021-07-09 上海市公共卫生临床中心 一种新型溶瘤病毒及其制备方法和应用
WO2022033469A1 (zh) * 2020-08-14 2022-02-17 上海行深生物科技有限公司 重组溶瘤病毒及其构建方法和用途
EP4288140A1 (en) 2021-02-05 2023-12-13 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1118403B (de) 1960-01-27 1961-11-30 Hoechst Ag Verfahren zur Gewinnung von antitumorwirksamen Sporen
GB1069144A (en) 1963-07-10 1967-05-17 Merck & Co Inc Method for the treatment of malignant tumors
US4806347A (en) 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
CA2132328C (en) 1992-03-24 2000-10-31 Laszlo K. Csatary Vaccine containing live virus for therapy of viral diseases and malignancies
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
US7153510B1 (en) * 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
AU1550797A (en) 1996-01-25 1997-08-20 Medical Research Council Treatment of non-neuronal cancer using hsv mutant
WO1999002657A1 (en) * 1997-07-11 1999-01-21 Yale University Rhabdoviruses with reengineered coats
IL135507A0 (en) 1997-10-09 2001-05-20 Pro Virus Inc Treatment of neoplasms with viruses
AP1968A (en) * 1997-12-22 2009-04-30 Univ Tennessee Res Corp Recombinant rhabdovirus containing a heterologous fusion protein.
AU3001799A (en) * 1998-03-12 1999-09-27 Trustees Of The University Of Pennsylvania, The Producer cells for replication selective viruses in the treatment of malignancy
IL140264A0 (en) 1998-06-12 2002-02-10 Sinai School Medicine Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
IL145899A0 (en) * 1999-04-15 2002-07-25 Pro Virus Inc Treatment of neoplasms with viruses

Also Published As

Publication number Publication date
JP5060694B2 (ja) 2012-10-31
NZ534306A (en) 2005-12-23
WO2001019380A3 (en) 2001-11-22
EP1716858B1 (en) 2008-12-24
IL148621A0 (en) 2002-09-12
EP1218019B1 (en) 2006-03-08
AU7588200A (en) 2001-04-17
EP1716858A3 (en) 2007-08-15
HK1044708A1 (en) 2002-11-01
ATE319460T1 (de) 2006-03-15
CA2386920C (en) 2012-01-24
NZ534307A (en) 2005-07-29
AU782402B2 (en) 2005-07-28
CN1289098C (zh) 2006-12-13
ES2320239T3 (es) 2009-05-20
NZ517573A (en) 2004-02-27
NZ523805A (en) 2004-09-24
DE60026554D1 (de) 2006-05-04
CN1496268A (zh) 2004-05-12
IL148621A (en) 2010-02-17
ES2260057T3 (es) 2006-11-01
CA2386920A1 (en) 2001-03-22
HK1092713A1 (en) 2007-02-16
EP1716858B9 (en) 2009-08-12
DE60041210D1 (de) 2009-02-05
EP1218019A2 (en) 2002-07-03
DE60026554T2 (de) 2006-09-28
HK1044708B (zh) 2006-10-27
JP2004525855A (ja) 2004-08-26
EP1716858A2 (en) 2006-11-02
WO2001019380A2 (en) 2001-03-22
ATE418341T1 (de) 2009-01-15

Similar Documents

Publication Publication Date Title
MXPA02002772A (es) Virus oncolitico.
DE60239394D1 (de) Onkolytische virustherapie
MY133891A (en) Polyethylene glycol modified interferon therapy
LU93101I2 (fr) Imlygic-talimogene laherparepvec
HUP0102441A2 (hu) Megváltozott interferon-antagonista aktivitással rendelkező, legyengített negatívszálú vírusok vakcinaként és gyógyszerként való alkalmazásra
DE69528751T2 (de) Verwendung von Interferon-alpha 8 subtype zur Herstellung von Medikamenten zur Behandlung von Viralinfektionen der Leber
DK0911033T4 (da) Anvendelse af konsensusinterferon til reduktion af bivirkningerne af interferonbehandling i viral hepatitis
EP1217891A4 (en) THERAPEUTIC PROCEDURES AND COMPOSITIONS USING VIRUSES FROM THE RECOMBINANT FAMILY OF THE PARAMYXOVIRIDAE
DE60136381D1 (de) Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität
FI940375A0 (fi) Peptidit, joilla on elimiä suojaavaa vaikutusta, menetelmä niiden valmistamiseksi ja niiden käyttö terapiassa
BR0109928A (pt) Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal
YU23993A (sh) Preparati za tretiranje infekcija i oboljenja izazvanih virusom hepatitisa b
WARFEL et al. Production and initial characterization of guinea pig interferon
DE69126977T2 (de) Verwendung von Leukoregulin zur Behandlung von mit einem envelope-Virus infizierten Tier
EP1143981A4 (en) TREATMENT AND PREVENTION OF HIV AND OTHER VIRUS INFECTIONS
SG165996A1 (en) Combination therapies with l-fmau for the treatment of hepatitis b virus infection
WO2003017943A3 (en) Therapeutic compositions and methods for treating viral infection
Eylan et al. Resistance of aged cells to virus replication
Czarniecki et al. Disparate response of encephalomyocarditis virus and MM virus to interferon in JLS-V9R cells
DE69916022D1 (de) Verwendung von il-11 zur verstärkung der zellvermittelten immunität zur behandlung verschiedener viraler und parasitärer infektionen und krebs
DK1250422T3 (da) Myeloid-kolonistimulerende faktor og anvendelser deraf
DK0979093T3 (da) Terapeutisk virusmiddel, hvis udvikling kan standses
SU1565027A1 (ru) Инактиватор вируса западного нила
GB1300567A (en) Therapeutic compositions
TH23210EX (th) "อนุพันธุ์พลาวินใช้เป็นสารต่อต้านไวรัส"

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status